Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citation
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Diet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Gut microbiota in cardiovascular health and disease
Tang, W. H. W., Kitai, T., & Hazen, S. L. (2017) · Circulation Research · doi:10.1161/circresaha.117.309715 · Cited by 1,670
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Dietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Self-citationChávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Huang, F., Zheng, X., Ma, X., Jiang, R., Zhou, W., Zhou, S., Zhang, Y., Lei, S., Wang, S., Kuang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12896-x · Cited by 789
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Role of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
“Conversely, a series of recently published studies provides compelling evidence suggesting that antagonism of intestinal FXR signaling improves metabolic parameters, including NAFLD, in mouse models of obesity.((51,83)) Intestinal FXR antagonism is mediated by muricholic acid derivatives, which are generated by GM and…”
BackgroundInfluentialRole and Mechanism of Gut Microbiota in Human Disease
Chen, Y., Zhou, J., & Wang, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.625913 · Cited by 627
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580
Pathak, P., Xie, C., Nichols, R. G., Ferrell, J. M., Boehme, S., Krausz, K. W., Patterson, A. D., Gonzalez, F. J., & Chiang, J. Y. L. (2018) · Hepatology · doi:10.1002/hep.29857 · Cited by 567
“Thus, activation of TGR5/ GLP-1 signaling through modulation of the gut microbiota may have therapeutic potential for treating NAFLD, diabetes, and obesity.”
BackgroundInfluentialSelf-citationIntestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559
Self-citationBile Acid Metabolism in Liver Pathobiology
Chiang, J. Y. L., & Ferrell, J. M. (2018) · Gene Expression · doi:10.3727/105221618x15156018385515 · Cited by 546
Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
Fiorucci, S., & Distrutti, E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.001 · Cited by 539
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Self-citationFXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
Clifford, B. L., Sedgeman, L. R., Williams, K. J., Morand, P., Cheng, A., Jarrett, K. E., Chan, A. P., Brearley-Sholto, M. C., Wahlström, A., Ashby, J. W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.012 · Cited by 487
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Microbiota-induced obesity requires farnesoid X receptor
Parséus, A., Sommer, N., Sommer, F., Caesar, R., Molinaro, A., Ståhlman, M., Greiner, T. U., Perkins, R., & Bäckhed, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310283 · Cited by 474
Bile acids in glucose metabolism in health and disease
Shapiro, H., Kolodziejczyk, A. A., Halstuch, D., & Elinav, E. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171965 · Cited by 464
Microbiota-gut-brain axis: Modulator of host metabolism and appetite
van de Wouw, M., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.240481 · Cited by 461
Targeting a ceramide double bond improves insulin resistance and hepatic steatosis
Chaurasia, B., Tippetts, T. S., Mayoral Monibas, R., Liu, J., Li, Y., Wang, L., Wilkerson, J. L., Sweeney, C. R., Pereira, R. F., Sumida, D. H., et al. (2019) · Science · doi:10.1126/science.aav3722 · Cited by 450
Bile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 437
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 435
Self-citationThe role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 407
Self-citationGu, Y., Wang, X., Li, J., Zhang, Y., Zhong, H., Liu, R., Zhang, D., Feng, Q., Xie, X., Hong, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01682-2 · Cited by 401
Self-citationAn Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 372
Self-citationCeramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
The chicken gut metagenome and the modulatory effects of plant-derived benzylisoquinoline alkaloids
Huang, P., Zhang, Y., Xiao, K., Jiang, F., Wang, H., Tang, D., Liu, D., Liu, B., Liu, Y., He, X., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0590-5 · Cited by 340
Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs
Ahmad, T. R., & Haeusler, R. A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0266-7 · Cited by 337
Gut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
“synthesis of triglycerides in the liver [8, 9]; modulation of endocannabinoid system [10, 11]; modulation of choline metabolism (which is required for very-low-density lipoprotein synthesis and hepatic lipid export) [12, 13]; modulation of bile acid homeostasis [14, 15]; the ability to generate endogenous ethanol [16,…”
BackgroundSphingolipids in metabolic disease: The good, the bad, and the unknown
Green, C. D., Maceyka, M., Cowart, L. A., & Spiegel, S. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.006 · Cited by 327
Kuang, J., Wang, J., Li, Y., Li, M., Zhao, M., Ge, K., Zheng, D., Cheung, K. C. P., Liao, B., Wang, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.011 · Cited by 321
Self-citationCyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
Takahashi, S., Fukami, T., Masuo, Y., Brocker, C. N., Xie, C., Krausz, K. W., Wolf, C. R., Henderson, C. J., & Gonzalez, F. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m071183 · Cited by 313
Self-citationLipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
Zhang, L., Nichols, R. G., Correll, J., Murray, I. A., Tanaka, N., Smith, P. B., Hubbard, T. D., Sebastian, A., Albert, I., Hatzakis, E., et al. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1409055 · Cited by 302
Self-citationGut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
Shen, Y., Fan, N., Ma, S., Cheng, X., Yang, X., & Wang, G. (2025) · MedComm · doi:10.1002/mco2.70168 · Cited by 301
Metabolic Messengers: ceramides
Summers, S. A., Chaurasia, B., & Holland, W. L. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0134-8 · Cited by 299
Gut-Resident Lactobacilli Activate Hepatic Nrf2 and Protect Against Oxidative Liver Injury
Saeedi, B. J., Liu, K. H., Owens, J. A., Hunter-Chang, S., Camacho, M. C., Eboka, R. U., Chandrasekharan, B., Baker, N. F., Darby, T. M., Robinson, B. S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.006 · Cited by 295
Bile acid metabolism and signaling in liver disease and therapy
Chiang, J. Y. L. (2017) · Liver Research · doi:10.1016/j.livres.2017.05.001 · Cited by 294
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Wang, L., Griffiths, C., Brown, M. L., Scott, W. E., et al. (2023) · Nature · doi:10.1038/s41586-022-05594-0 · Cited by 293
Hartmann, P., Hochrath, K., Horvath, A., Chen, P., Seebauer, C. T., Llorente, C., Wang, L., Alnouti, Y., Fouts, D. E., Stärkel, P., et al. (2018) · Hepatology · doi:10.1002/hep.29676 · Cited by 290
“FXR activity can be induced by conjugated bile acids(29) and, to some degree, by TCA.”
InfluentialDiscovery of farnesoid X receptor and its role in bile acid metabolism
Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 288
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 287
Rom, O., Liu, Y., Liu, Z., Zhao, Y., Wu, J., Ghrayeb, A., Villacorta, L., Fan, Y., Chang, L., Wang, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2841 · Cited by 280
Animal models to study bile acid metabolism
Li, J., & Dawson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.011 · Cited by 255
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility
Wei, M., Huang, F., Zhao, L., Zhang, Y., Yang, W., Wang, S., Li, M., Han, X., Ge, K., Qu, C., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102766 · Cited by 253
Pathak, P., Liu, H., Boehme, S., Xie, C., Krausz, K. W., Gonzalez, F., & Chiang, J. Y. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784322 · Cited by 253
Self-citationHypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets
Zhao, Y., Xiong, W., Li, C., Zhao, R., Lu, H., Song, S., Zhou, Y., Hu, Y., Shi, B., & Ge, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01652-9 · Cited by 249
“470,471 An inhibitory effect of ceramide on hepatic cholesterol elimination, achieved through the suppression of hepatic Cyp7a1 and Abcg5/8 , was observed.”
BackgroundNon-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241
“These intestinal FXR deficient HFD mice, but not liver-specific-FXR deficient mice [112], had lower hepatic triglycerides and reduced liver steatosis as compared to controls [118].”
BackgroundNatural history of metabolic dysfunction-associated steatotic liver disease
Lekakis, V., & Papatheodoridis, G. V. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.11.005 · Cited by 233
Diet, genetics, and the gut microbiome drive dynamic changes in plasma metabolites
Fujisaka, S., Avila-Pacheco, J., Soto, M., Kostic, A., Dreyfuss, J. M., Pan, H., Ussar, S., Altindis, E., Li, N., Bry, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.060 · Cited by 231
“For example, primary bile acids are converted to secondary bile acids by gut microbiotas, and these secondary bile acids not only aid in fat absorption, but they also are reabsorbed into the circulation, where they serve as ligands for the bile acid receptors farnesoid X (FXR) and TGR5 on host cells, leading to effect…”
BackgroundThe microbiome and autoimmunity: a paradigm from the gut–liver axis
Li, B., Selmi, C., Tang, R., Gershwin, M. E., & Ma, X. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2018.7 · Cited by 229
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227
“antagonism in the field of metabolic liver diseases,((40,80,81)) it will be interesting to see whether this also applies to cholestatic disorders.”
Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia
Jia, X., Xu, W., Zhang, L., Li, X., Wang, R., & Wu, S. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.634780 · Cited by 226
Self-citationHerbal drug discovery for the treatment of nonalcoholic fatty liver disease
Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.017 · Cited by 224
Self-citationFXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Wang, X. X., Wang, D., Luo, Y., Myakala, K., Dobrinskikh, E., Rosenberg, A. Z., Levi, J., Kopp, J. B., Field, A., Hill, A., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017020222 · Cited by 222
Self-citationPathogenesis of nonalcoholic steatohepatitis
Liu, W., Baker, R. D., Bhatia, T., Zhu, L., & Baker, S. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2161-x · Cited by 221
Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition
Honda, A., Miyazaki, T., Iwamoto, J., Hirayama, T., Morishita, Y., Monma, T., Ueda, H., Mizuno, S., Sugiyama, F., Takahashi, S., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000395 · Cited by 213
Self-citationTargeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
Self-citationRao, A., Kosters, A., Mells, J. E., Zhang, W., Setchell, K. D. R., Amanso, A. M., Wynn, G. M., Xu, T., Keller, B. T., Yin, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4823 · Cited by 211
“Administration of an ASBTi does not alter ceramides in HFD-fed mouse ileum or liver Recent studies in a different HFD-fed mouse model (8, 18) support a role for ileal FXR signaling–associated changes in ceramide synthesis and secretion into the portal circulation in the development of fatty liver”
BackgroundIntestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q.-H., & Di Ciaula, A. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 211
Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis
Kasumov, T., Li, L., Li, M., Gulshan, K., Kirwan, J. P., Liu, X., Previs, S., Willard, B., Smith, J. D., & McCullough, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126910 · Cited by 209
Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease
Wieland, A., Frank, D. N., Harnke, B., & Bambha, K. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13376 · Cited by 207
Sun, L., Pang, Y., Wang, X., Wu, Q., Liu, H., Liu, B., Liu, G., Ye, M., Kong, W., & Jiang, C. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.02.004 · Cited by 204
Self-citationZhao, L., Yang, W., Chen, Y., Huang, F., Lu, L., Lin, C., Huang, T., Ning, Z., Zhai, L., Zhong, L. L. D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130976 · Cited by 202
Guan, B., Tong, J., Hao, H., Yang, Z., Chen, K., Xu, H., & Wang, A. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.011 · Cited by 202
An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
Xie, C., Jiang, C., Shi, J., Gao, X., Sun, D., Sun, L., Wang, T., Takahashi, S., Anitha, M., Krausz, K. W., et al. (2017) · Diabetes · doi:10.2337/db16-0663 · Cited by 201
“Primary Hepatocyte Cultures and Treatment Primary hepatocytes were isolated as previously described (9).”
BackgroundMethodInfluentialSelf-citationXu, H., Fang, F., Wu, K., Song, J., Li, Y., Lu, X., Liu, J., Zhou, L., Yu, W., Yu, F., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01709-5 · Cited by 199
The role of the gut microbiota in metabolic health
Janssen, A. W. F., & Kersten, S. (2015) · The FASEB Journal · doi:10.1096/fj.14-269514 · Cited by 197
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
Ma, J., Zhou, Q., & Li, H. (2017) · Nutrients · doi:10.3390/nu9101124 · Cited by 197
Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis
Jia, W., Li, Y., Cheung, K. C. P., & Zheng, X. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2353-0 · Cited by 189
Update on FXR Biology: Promising Therapeutic Target?
Han, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072069 · Cited by 185
Pathogenesis and novel treatment options for non-alcoholic steatohepatitis
Wong, V. W.-S., Chitturi, S., Wong, G. L.-H., Yu, J., Chan, H. L.-Y., & Farrell, G. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30011-5 · Cited by 185
Short Chain Fatty Acid Metabolism in Relation to Gut Microbiota and Genetic Variability
Ramos Meyers, G., Samouda, H., & Bohn, T. (2022) · Nutrients · doi:10.3390/nu14245361 · Cited by 184
Ding, L., Sousa, K. M., Jin, L., Dong, B., Kim, B., Ramirez, R., Xiao, Z., Gu, Y., Yang, Q., Wang, J., et al. (2016) · Hepatology · doi:10.1002/hep.28689 · Cited by 184
Feng, S., Dai, Z., Liu, A. B., Huang, J., Narsipur, N., Guo, G., Kong, B., Reuhl, K., Lu, W., Luo, Z., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.08.004 · Cited by 183
Recent advances in understanding bile acid homeostasis
Chiang, J. Y. (2017) · F1000Research · doi:10.12688/f1000research.12449.1 · Cited by 181
“Deficiency of intestinal FXR or antagonizing FXR by an antioxidant, Tempol or Gly-MCA, an MCA derivative that is resistant to BSH activity, prevents DIO 18,19 .”
BackgroundPortincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 181
Duparc, T., Plovier, H., Marrachelli, V. G., Van Hul, M., Essaghir, A., Ståhlman, M., Matamoros, S., Geurts, L., Pardo-Tendero, M. M., Druart, C., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310904 · Cited by 177
The Role of the Gut Microbiota in the Pathogenesis of Diabetes
Bielka, W., Przezak, A., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010480 · Cited by 176
FXR in liver physiology: Multiple faces to regulate liver metabolism
Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 157
Pathophysiological role of host microbiota in the development of obesity
Kobyliak, N., Virchenko, O., & Falalyeyeva, T. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0166-9 · Cited by 149
The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
Song, Q., & Zhang, X. (2022) · Biomedicines · doi:10.3390/biomedicines10030524 · Cited by 175
Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery
Albaugh, V. L., Banan, B., Antoun, J., Xiong, Y., Guo, Y., Ping, J., Alikhan, M., Clements, B. A., Abumrad, N. N., & Flynn, C. R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.017 · Cited by 173
Visekruna, A., & Luu, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703218 · Cited by 174
Xu, Y., Li, F., Zalzala, M., Xu, J., Gonzalez, F. J., Adorini, L., Lee, Y., Yin, L., & Zhang, Y. (2016) · Hepatology · doi:10.1002/hep.28712 · Cited by 172
“1 3 100 mm) coupled to a Waters Xevo G2 QTOFMS, as described.((32))”
MethodSelf-citationMa, J., Hong, Y., Zheng, N., Xie, G., Lyu, Y., Gu, Y., Xi, C., Chen, L., Wu, G., Li, Y., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1763770 · Cited by 171
“It has been shown that intestinal FXR deficient mice are resistant to dietinduced steatohepatitis, obesity, and insulin resistance.(15,82) Therefore, old mice may have elevated intestinal Tα+βMCA levels to present beneficial effects while co-housed mice do not need to maintain high Tα+βMCA levels.”
BackgroundImpact of Microbial Metabolites on Microbiota–Gut–Brain Axis in Inflammatory Bowel Disease
Banfi, D., Moro, E., Bosi, A., Bistoletti, M., Cerantola, S., Crema, F., Maggi, F., Giron, M. C., Giaroni, C., & Baj, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041623 · Cited by 173
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.